POLIVY (polatuzumab vedotin-piiq) is an FDA-approved treatment for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have already received at least 2 prior therapies. It is used in combination with 2 other cancer treatments: bendamustine and a rituximab product (BR).
POLIVY received an accelerated approval from the FDA. This conditional approval helps patients get earlier access to a promising drug while the company continues to conduct clinical trials to establish how the drug works.
POLIVY is a type of medicine called an antibody-drug conjugate, or ADC. POLIVY is designed to work differently from traditional chemotherapies because it has the ability to find dividing B cells, including cancerous B cells.
Almost all B cells (including cancerous ones) have a marker on their surface called CD79b. POLIVY works by finding and attaching to B cells using the CD79b marker.
Illustration of an antibody-drug conjugate (ADC)
*Antibodies are also produced naturally by the body. They are a type of protein that acts as a natural defense system against disease.
The information contained in this section of the site is intended for US healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.